Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | ALPHA trial: ALLO-501 in relapsed/refractory non-Hodgkin lymphoma

Sattva Neelapu • 29 May 2020
ASCO 2020
Diffuse Large B-Cell Lymphoma Follicular Lymphoma Non-Hodgkin Lymphoma ALLO-501
ALPHA

Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, describes the Phase I ALPHA study (NCT03939026), evaluating the safety and efficacy of ALLO-501, an anti-CD19 allogeneic CAR T-cell in adults with relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL; FL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sattva Neelapu

Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL
4:50
Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL
Sattva Neelapu • 12 Dec 2024
Next steps with ADI-001
0:42
Next steps with ADI-001
Sattva Neelapu • 5 Jun 2022
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
2:06
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu • 5 Jun 2022
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
3:24
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu • 5 Jun 2022

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals